目的观察祝氏降糖对药方对社区慢性阻塞性肺疾病(COPD)合并糖尿病患者血糖水平及呼吸功能影响。方法研究纳入社区收治的114例慢性阻塞性肺疾病合并糖尿病患者(2022年3月—2023年2月收治)作为本次研究对象,以随机数字表法将患者分为观察...目的观察祝氏降糖对药方对社区慢性阻塞性肺疾病(COPD)合并糖尿病患者血糖水平及呼吸功能影响。方法研究纳入社区收治的114例慢性阻塞性肺疾病合并糖尿病患者(2022年3月—2023年2月收治)作为本次研究对象,以随机数字表法将患者分为观察组与对照组,各组57例,对照组患者给予社区常规疗法,观察组患者在社区常规疗法治疗基础上给予患者祝氏降糖对药方治疗,各组数据观察:治疗前后患者空腹血糖(FPG)及餐后2h血糖(2 h PG)、糖化血红蛋白(HbA1c)指标变化,用力肺活量(FVC)及一秒用力呼气容积(FEV_(1))、FEV_(1)/FVC等呼吸功能指标、6 min步行距离变化及慢性阻塞性肺疾病评估测试(CAT)评分变化、改良英国医学研究委员会呼吸困难指数(mMRC)变化、患者治疗前后生活质量(SF-36)评分变化、治疗满意率。结果治疗前,各组患者FPG、2 h PG、HbA1c、FVC、FEV_(1)、FEV_(1)/FVC、6 min步行距离、CAT及mMRC评分、SF-36评分比较,P>0.05,治疗后各组患者FPG、2 h PG、HbA1c、FVC、FEV_(1)、FEV_(1)/FVC、6 min步行距离、CAT及mMRC评分、SF-36评分等指标均改善,观察组患者治疗后FPG、2 h PG、HbA1c、FVC、FEV_(1)、FEV_(1)/FVC、6 min步行距离、CAT及mMRC评分、SF-36评分等指标优于对照组,P<0.05;观察组患者治疗满意率(98.25%)均高于对照组患者(85.96%),P<0.05。结论祝氏降糖对药方有助于稳定COPD合并糖尿病患者病情,患者血糖水平降低,呼吸功能改善,生活质量提升,患者较为认可与满意,值得应用。展开更多
Using patch clamp whole cell recording techiques, we examined the effects ofIQ<sub>2</sub>3, a benzyl-isoquinoline derivative with antiarrhythmic activities, on the action potential （AP） andpotassium cur...Using patch clamp whole cell recording techiques, we examined the effects ofIQ<sub>2</sub>3, a benzyl-isoquinoline derivative with antiarrhythmic activities, on the action potential （AP） andpotassium currents in single guinea pig ventricular myocytes. The results showed that IQ<sub>2</sub>3 at 10, 30and 100 μmol ·L<sub>-</sub>1 slowed the repolarization in AP dose-dependently. The APD<sub>9</sub>0 were prolonged by15%, 28% and 31% respectively. This effect did not depend on the extracellular Ca<sup>2</sup>+. In voltageclamp mode, IQ<sub>2</sub>3 effectively blocked both the components of the delayed rectifier potassium current（I<sub>k</sub>）, i.e., I<sub>k</sub>s and I<sub>k</sub>r. At concentrations of 30 and 100 μmol· L<sup>-</sup>1, IQ<sub>2</sub>3 suppressed I<sub>k</sub>s by 21% and 26%and suppressed I<sub>k</sub>r by 67% and 86% respectively. But even at 100 μmol·L<sup>-</sup>1, IQ<sub>2</sub>3 had little effect onthe inward rectifier potassium current （I<sub>k</sub>1）. It is concluded: 1. IQ<sub>2</sub>3 can dose-dependently prolongAPD in the ventriculas myocytes of guinea pig, the effect does not depend on the extracellular Ca<sup>2</sup>+; 2.IQ<sub>2</sub>3 blocks both I<sub>k</sub>s and Ikr in the ventricular myocytes without obvious specificities between them.展开更多
文摘目的观察祝氏降糖对药方对社区慢性阻塞性肺疾病(COPD)合并糖尿病患者血糖水平及呼吸功能影响。方法研究纳入社区收治的114例慢性阻塞性肺疾病合并糖尿病患者(2022年3月—2023年2月收治)作为本次研究对象,以随机数字表法将患者分为观察组与对照组,各组57例,对照组患者给予社区常规疗法,观察组患者在社区常规疗法治疗基础上给予患者祝氏降糖对药方治疗,各组数据观察:治疗前后患者空腹血糖(FPG)及餐后2h血糖(2 h PG)、糖化血红蛋白(HbA1c)指标变化,用力肺活量(FVC)及一秒用力呼气容积(FEV_(1))、FEV_(1)/FVC等呼吸功能指标、6 min步行距离变化及慢性阻塞性肺疾病评估测试(CAT)评分变化、改良英国医学研究委员会呼吸困难指数(mMRC)变化、患者治疗前后生活质量(SF-36)评分变化、治疗满意率。结果治疗前,各组患者FPG、2 h PG、HbA1c、FVC、FEV_(1)、FEV_(1)/FVC、6 min步行距离、CAT及mMRC评分、SF-36评分比较,P>0.05,治疗后各组患者FPG、2 h PG、HbA1c、FVC、FEV_(1)、FEV_(1)/FVC、6 min步行距离、CAT及mMRC评分、SF-36评分等指标均改善,观察组患者治疗后FPG、2 h PG、HbA1c、FVC、FEV_(1)、FEV_(1)/FVC、6 min步行距离、CAT及mMRC评分、SF-36评分等指标优于对照组,P<0.05;观察组患者治疗满意率(98.25%)均高于对照组患者(85.96%),P<0.05。结论祝氏降糖对药方有助于稳定COPD合并糖尿病患者病情,患者血糖水平降低,呼吸功能改善,生活质量提升,患者较为认可与满意,值得应用。
文摘Using patch clamp whole cell recording techiques, we examined the effects ofIQ<sub>2</sub>3, a benzyl-isoquinoline derivative with antiarrhythmic activities, on the action potential （AP） andpotassium currents in single guinea pig ventricular myocytes. The results showed that IQ<sub>2</sub>3 at 10, 30and 100 μmol ·L<sub>-</sub>1 slowed the repolarization in AP dose-dependently. The APD<sub>9</sub>0 were prolonged by15%, 28% and 31% respectively. This effect did not depend on the extracellular Ca<sup>2</sup>+. In voltageclamp mode, IQ<sub>2</sub>3 effectively blocked both the components of the delayed rectifier potassium current（I<sub>k</sub>）, i.e., I<sub>k</sub>s and I<sub>k</sub>r. At concentrations of 30 and 100 μmol· L<sup>-</sup>1, IQ<sub>2</sub>3 suppressed I<sub>k</sub>s by 21% and 26%and suppressed I<sub>k</sub>r by 67% and 86% respectively. But even at 100 μmol·L<sup>-</sup>1, IQ<sub>2</sub>3 had little effect onthe inward rectifier potassium current （I<sub>k</sub>1）. It is concluded: 1. IQ<sub>2</sub>3 can dose-dependently prolongAPD in the ventriculas myocytes of guinea pig, the effect does not depend on the extracellular Ca<sup>2</sup>+; 2.IQ<sub>2</sub>3 blocks both I<sub>k</sub>s and Ikr in the ventricular myocytes without obvious specificities between them.
